US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

First Tracks Biotherapeutics Inc

31.54

-2.5100-7.37%

Volume:588.25K

Turnover:18.93M

Market Cap:1.13B

PE:-6.96

High:34.36

Open:33.72

Low:31.12

Close:34.05

52wk High:49.91

52wk Low:14.72

Shares:35.73M

Float Shares:34.75M

Volume Ratio:0.35

T/O Rate:1.69%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-4.5296

ROE:-48.91%

ROA:-28.97%

PB:6.68

PE(LYR):- -

Loading ...

Overview Company News Filings

First Tracks Biotherap Price Target Raised to $70.00/Share from $65.00 by Evercore ISI Group

Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)

US Research Roundup-Essex Property Trust, Qualys, Vulcan Materials

US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences

First Tracks Biotherapeutics Shares Rise 13.3% Premarket After Positive Results from Celiac Disease Drug Trial

THOMSON REUTERS

First Tracks Reports Positive Trial Results for Celiac-Disease Treatment

First Tracks Says Anb033 Meets Key Histologic, Symptom Endpoints in Phase 1b Celiac Gluten-Challenge Study

First Tracks Biotherapeutics - Anb033 Achieves Statistically Significant Protective Effect in Celiac Disease Phase 1B Trial

THOMSON REUTERS

First Tracks Biotherapeutics - Anb033 Phase 2 Development in Vitiligo and Additional Indication to Initiate in H1 2027

THOMSON REUTERS

First Tracks Biotherapeutics - Anb033 Phase 1B Cohort in Eosinophilic Esophagitis Top-Line Data Expected Q3 2027

THOMSON REUTERS

First Tracks Biotherapeutics Announces Positive Top-Line Results for Anb033 in Gluten-Challenge Study in Celiac Disease

THOMSON REUTERS

First Tracks Biotherapeutics - Anb033 Shows +0.49 Placebo-Adj Delta in Vh:Cd Ratio (p=0.009) at Week 6

THOMSON REUTERS

First Tracks Biotherapeutics - Anb033 Well Tolerated with no Safety Signals Observed to Date

THOMSON REUTERS

First Tracks Shares Climb Ahead of Early-Stage Trial Readout

Analysts Offer Insights on NA Companies: American Integrity Insurance Group, Inc. (AII) and First Tracks Biotherapeutics Inc (TRAX)

First Tracks Biotherapeutics to Release Phase 1b Cohort 1 Data for Anb033 in Celiac Disease Oct. 12

First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1B Trial of Anb033, a Cd122 Antagonist, in Celiac Disease on Oct. 12, 2026

THOMSON REUTERS

Wells Fargo Keeps Their Buy Rating on First Tracks Biotherapeutics Inc (TRAX)

Analysts Conflicted on These NA Names: Amrize Ltd (AMRZ) and First Tracks Biotherapeutics Inc (TRAX)

First Tracks Biotherapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $50

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au.tigermarketd.com/stock/TRAX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental","symbol":"TRAX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAX\",,,,,undefined,":{"symbol":"TRAX","market":"US","secType":"STK","nameCN":"First Tracks Biotherapeutics Inc","latestPrice":31.54,"timestamp":1791916513033,"preClose":34.05,"halted":0,"volume":588248,"delay":0,"changeRate":-0.07371512481644635,"floatShares":34748800,"shares":35730843,"eps":-4.529554,"marketStatus":"Trading","change":-2.51,"latestTime":"10-13 14:35:18 EDT","open":33.72,"high":34.355,"low":31.12,"amount":18925712.315968,"amplitude":0.095007,"askPrice":31.55,"askSize":102,"bidPrice":31.42,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-4.529554,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791921600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":34.05,"preHourTrading":{"tag":"盘前","latestPrice":33.67,"preClose":34.05,"latestTime":"09:29 EDT","volume":1861,"amount":63046.12055,"timestamp":1791898141091,"change":-0.38,"changeRate":-0.01116,"amplitude":0.089736},"postHourTrading":{"tag":"盘后","latestPrice":34,"preClose":34.05,"latestTime":"19:59 EDT","volume":19763,"amount":668113.0978,"timestamp":1791849596318,"change":-0.05,"changeRate":-0.001468,"amplitude":0.0279},"volumeRatio":0.352974,"impliedVol":0.9273,"impliedVolPercentile":0.5833},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TRAX\",,,,,undefined,":{"symbol":"TRAX","floatShares":34748800,"roa":"-28.97%","roe":"-48.91%","lyrEps":0,"volumeRatio":0.352974,"shares":35730843,"dividePrice":0,"high":34.355,"amplitude":0.095007,"preClose":34.05,"low":31.12,"week52Low":14.72,"pbRate":"6.68","week52High":49.9114,"institutionHeld":0,"latestPrice":31.54,"committee":0.66113,"eps":-4.529554,"divideRate":0,"volume":588248,"delay":0,"ttmEps":-4.529554,"open":33.72,"prevYearClose":20,"prevWeekClose":31.85,"prevMonthClose":35.44,"prevQuarterClose":35.44,"fiveDayClose":31.39,"twentyDayClose":38.47,"sixtyDayClose":36.87},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TRAX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-12","symbol":"TRAX","fiscalQuarterEnding":"2026/06","expectedEps":-0.74,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1786507200000,"reportTimeType":"post","actualEps":-0.95}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TRAX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TRAX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":12,"updateTime":1791000000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TRAX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TRAX","date":"2026-10-12","current":-6.952119,"percent":0.517241,"low":-10.141689,"twenty":-9.324113,"median":-7.212294,"eighty":-3.663211,"high":-3.156022,"avg":-6.463754,"sd":2.550844,"marketCap":1138027349},"quantilePoints":[{"date":"2026-04-24","current":-3.975194,"twenty":-3.975194,"median":-3.975194,"eighty":-3.975194,"marketCap":660227979},{"date":"2026-05-01","current":-4.868566,"twenty":-4.868566,"median":-4.085034,"eighty":-3.799448,"marketCap":808605530},{"date":"2026-05-08","current":-3.728313,"twenty":-4.68236,"median":-4.236719,"eighty":-3.799448,"marketCap":619224346},{"date":"2026-05-15","current":-3.799448,"twenty":-4.433387,"median":-4.031683,"eighty":-3.799448,"marketCap":631038952},{"date":"2026-05-22","current":-3.452672,"twenty":-4.299486,"median":-3.855938,"eighty":-3.664859,"marketCap":584796305},{"date":"2026-05-29","current":-3.259026,"twenty":-4.249272,"median":-3.799448,"eighty":-3.475745,"marketCap":551997467},{"date":"2026-06-05","current":-3.749322,"twenty":-4.203244,"median":-3.738817,"eighty":-3.411676,"marketCap":635041334},{"date":"2026-06-12","current":-3.508294,"twenty":-4.109513,"median":-3.726221,"eighty":-3.329068,"marketCap":594217248},{"date":"2026-06-18","current":-3.743141,"twenty":-4.020386,"median":-3.683399,"eighty":-3.361617,"marketCap":633994562},{"date":"2026-06-26","current":-3.372329,"twenty":-3.945066,"median":-3.663829,"eighty":-3.37851,"marketCap":571188276},{"date":"2026-07-02","current":-3.829664,"twenty":-3.955109,"median":-3.663829,"eighty":-3.376449,"marketCap":648649362},{"date":"2026-07-10","current":-6.674616,"twenty":-4.112294,"median":-3.726221,"eighty":-3.397462,"marketCap":1130513144},{"date":"2026-07-17","current":-7.459502,"twenty":-4.261943,"median":-3.735727,"eighty":-3.424655,"marketCap":1263453116},{"date":"2026-07-24","current":-7.754091,"twenty":-4.794084,"median":-3.774042,"eighty":-3.434543,"marketCap":1313349220},{"date":"2026-07-31","current":-9.842999,"twenty":-6.999282,"median":-3.799448,"eighty":-3.441135,"marketCap":1667157964},{"date":"2026-08-07","current":-9.334163,"twenty":-7.464446,"median":-3.842801,"eighty":-3.45844,"marketCap":1580973783},{"date":"2026-08-14","current":-9.814035,"twenty":-7.742967,"median":-3.975194,"eighty":-3.486045,"marketCap":1573229017},{"date":"2026-08-21","current":-9.33927,"twenty":-8.651869,"median":-4.081492,"eighty":-3.504998,"marketCap":1497122321},{"date":"2026-08-28","current":-9.97229,"twenty":-9.339073,"median":-4.144854,"eighty":-3.509324,"marketCap":1598597915},{"date":"2026-09-04","current":-9.475235,"twenty":-9.448042,"median":-4.257739,"eighty":-3.516946,"marketCap":1518918135},{"date":"2026-09-11","current":-8.465524,"twenty":-9.33927,"median":-4.366436,"eighty":-3.530954,"marketCap":1357057417},{"date":"2026-09-18","current":-8.737455,"twenty":-9.338283,"median":-4.868566,"eighty":-3.539195,"marketCap":1400649045},{"date":"2026-09-25","current":-7.986302,"twenty":-9.334163,"median":-6.877533,"eighty":-3.588636,"marketCap":1280236104},{"date":"2026-10-02","current":-7.560574,"twenty":-9.330354,"median":-7.443021,"eighty":-3.633958,"marketCap":1211990194},{"date":"2026-10-09","current":-7.134846,"twenty":-9.325896,"median":-7.282788,"eighty":-3.662799,"marketCap":1143744284},{"date":"2026-10-12","current":-7.099182,"twenty":-9.324113,"median":-7.212294,"eighty":-3.663211,"marketCap":1138027349}],"updateTime":1791916518912},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TRAX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2675361366","title":"First Tracks Biotherap Price Target Raised to $70.00/Share from $65.00 by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2675361366","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675361366?lang=en_us&edition=fundamental","pubTime":"2026-10-14 02:09","pubTimestamp":1791914940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TRAX/analyst-ratings","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675337633","title":"Barclays Sticks to Its Buy Rating for First Tracks Biotherapeutics Inc (TRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2675337633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675337633?lang=en_us&edition=fundamental","pubTime":"2026-10-13 17:16","pubTimestamp":1791883016,"startTime":"0","endTime":"0","summary":"In a report released today, Etzer Darout from Barclays maintained a Buy rating on First Tracks Biotherapeutics Inc, with a price target of $65.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-first-tracks-biotherapeutics-inc-trax-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-sticks-to-its-buy-rating-for-first-tracks-biotherapeutics-inc-trax-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675433488","title":"US Research Roundup-Essex Property Trust, Qualys, Vulcan Materials","url":"https://stock-news.laohu8.com/highlight/detail?id=2675433488","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2675433488?lang=en_us&edition=fundamental","pubTime":"2026-10-13 16:22","pubTimestamp":1791879773,"startTime":"0","endTime":"0","summary":"US RESEARCH ROUNDUP-Essex Property Trust, Qualys, Vulcan MaterialsOct 13 (Reuters)-Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Ess","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261013:nL4N45Z0NS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AVY","AMRZ","ESS","CPT","BMY","ASTS","CECO","ELS","EXLS","TRAX","POW","ALNT","EPAM","NETG","GPK","ETR","GDYN","FTNT","EFX","SMRF","CNP","AADX","ASTN","BWXT","EROK","HUN","NET","ASBH","UPW","BELFB","DUK","CUT","CC","ADIG","ESE","FPWR","JXI","GEL","CDRE","EMN","EFOR","AMH","VPU","WSPC","CE","RSPR","BALL","HUM","EXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674811808","title":"US Stocks on the MOVE-Salesforce, Brown & Brown, IonQ, Harmony Biosciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2674811808","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674811808?lang=en_us&edition=fundamental","pubTime":"2026-10-12 21:03","pubTimestamp":1791810185,"startTime":"0","endTime":"0","summary":"BUZZ-US STOCKS ON THE MOVE-Salesforce, Brown & Brown, IonQ, Harmony BiosciencesOct 12 (Reuters)-US stock indexes were on track for a muted open on Monday as investors watched oil prices and global eve","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nL4N45Y0RE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IONL","BK4579","LU0528227936.USD","LU1074936037.SGD","LU1496350502.SGD","LU0354030511.USD","LU1868836914.USD","LU2108987350.USD","LU0052756011.USD","BK4505","LU0068578508.USD","LU0211328371.USD","LU0061475181.USD","LU0889565916.HKD","LU0985481810.HKD","LU1323610961.USD","LU0353189680.USD","LU1366333091.USD","LU1989764664.SGD","WQTM","IREZ","LU0820561909.HKD","LU2756315318.SGD","LU1988902786.USD","LU0889566641.SGD","BK4591","IE00BSNM7G36.USD","LU0792757196.USD","IHE","IE00BZ1G4Q59.USD","LU0353189763.USD","BK4533","LU1093756325.SGD","LU2236285917.USD","LU0306807586.USD","LU1868836591.USD","LU0267386448.USD","LU0198837287.USD","IONZ","LU1815336760.USD","LU1201861165.SGD","IE00B19Z9Z06.USD","IE00BFXG1179.USD","FTXH","LU0006306889.USD","LU0943347566.SGD","LU2247934214.USD","IBLC","LU2265009873.SGD","IREC","LU0048573561.USD","BK4173","LU0957808578.USD","LU0820562030.AUD","LU0557290698.USD","IREN","FDIG","BK4007","LU1642822529.SGD","LU2286300806.USD","LU0306806265.USD","BK4170","IREG","BK4534","LU1803068979.SGD","LU2357305700.SGD","LU1951198990.SGD","BK4608","LU1670710661.SGD","LU2361044865.SGD","IE00BJJMRZ35.SGD","LU1983299246.USD","IE00BQXX3D17.EUR","LU1720051108.HKD","LU0985489474.SGD","LU1032466523.USD","LU0130518102.USD","LU2361044949.HKD","LU1804176565.USD","LU0109394709.USD","LU1989764748.USD","BK4528","LU0868494617.USD","LU0444971666.USD","STCE","IE00BFTCPJ56.SGD","BK4532","BK4023","LU1548497426.USD","BK4597","LU0234570918.USD","LU1093756168.USD","LU2095319765.USD","BK4613","IE00BJTD4N35.SGD","LU0187121727.USD","IE00B19Z9505.USD","LU0211327993.USD","LU0310800965.SGD","LU2458330169.SGD","LU0689472784.USD","IE0009355771.USD","LU0314104364.USD","TRAX","BK4561","LU0976567544.SGD","BK4096","GDDY","LU0127658192.USD","LU0476273544.USD","BK4567","LU0109392836.USD","LU0444973449.USD","CRMG","LU1670710588.SGD","LU0289739343.SGD","LU2210150020.SGD","LU2361045086.USD","LU2125154778.USD","BK4527","BK4602","IONQ","LU0114720955.EUR","LU1496350171.SGD","LU2458330243.SGD","IREX","LU0321505439.SGD","LU1430594728.SGD","LU1883839398.USD","IE0002141913.USD","BK4595","BK4581","LU0082616367.USD","LU0289961442.SGD","LU0980610538.SGD","IE00BKVL7J92.USD","LU0648001328.SGD","BK4600","BRO","BK4516","LU0057025933.USD","LU0477156953.USD","LU1236620834.HKD","LU1823568750.SGD","LU0432979614.USD","LU1064131342.USD","LU0648000940.SGD","LU2210149790.SGD","BK4124","IE00B2B36J28.USD","LU0742534661.SGD","BK4550","IE00B19Z9P08.USD","LU0237698245.USD","LU1880398471.USD","LU1951200564.SGD","LU0251142724.SGD","LU1923623000.USD","LU0496365809.HKD","LU0310799852.SGD","LU1291159041.SGD","BK4535","LU1046421795.USD","DCH","LU0157215616.USD","BK4607","LU0124676726.USD","LU2242646821.SGD","MNRS","LU1814569148.SGD","IE00BJT1NW94.SGD","LU0354030438.USD","LU1989771016.USD","IE0008368304.USD","LU1261432733.SGD","LU1489326972.SGD","ENVX","IOYY","LU0225284248.USD","LU1670711040.USD","LU0211326755.USD","BK4548","LU0321505868.SGD","IE00BQXX3C00.GBP","LU0106261372.USD","LU1551013425.SGD","CQTM","LU0069063385.USD","LU0882574055.USD","LU1670711123.USD","BMY","LU0820561818.USD","LU1571399168.USD","BK4598","LU1267930813.SGD","LU0472753341.HKD","LU0320765992.SGD","LU2133065610.SGD","DAPP","BK4559","IE00B19Z8X17.USD","LU2461242641.AUD","LU1235294995.USD","LU2491050071.SGD","LU2756315664.SGD","IRE","LU0251131958.USD","LU0130102774.USD","BK4139","IE00BKPKM429.USD","LU0238689110.USD","LU2264538146.SGD","LU2242652126.USD","LU1267930490.SGD","LU1236620750.USD","LU1868837136.USD","LU1868837300.USD","LU1551013342.USD","LU1316542783.SGD","LU2087625088.SGD","BK4585","LU1791710400.SGD","LU0225771236.USD","IE00BJTD4V19.USD","BKCH","LU0689626769.HKD","LU0081259029.USD","LU0477156797.USD","LU0130103400.USD","IE00BQXX3F31.USD","LU0234572021.USD","LU1880398554.USD","BK4588","LU0211326839.USD","LU1718418525.SGD","LU0511384066.AUD","CRM","LU1868836757.USD","LU0130517989.USD","IE00B19Z8W00.USD","IE00B894F039.SGD","LU0211331839.USD","LU0128525689.USD","LU2125154935.USD","BK4141","BK4538","LU0433182093.SGD","LU0719512351.SGD","PBE","IONC","LU0878866978.SGD","LU1585245621.USD","LU1791710582.SGD","WGMI","BITQ","BIIB","LU2491050154.USD","HRMY","LU2360032135.SGD","BK4543","LU0456855351.SGD","LU0642271901.SGD","LU0889565833.HKD","LU2491049909.HKD","QTUP","IONX","LU1720051017.SGD","LU2244417387.USD","BK4116","LU2596442595.SGD","LU1201861249.SGD","LU1267930227.SGD","LU0096364046.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674877450","title":"First Tracks Biotherapeutics Shares Rise 13.3% Premarket After Positive Results from Celiac Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674877450","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674877450?lang=en_us&edition=fundamental","pubTime":"2026-10-12 20:15","pubTimestamp":1791807300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nFWN45Y20W:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674642872","title":"First Tracks Reports Positive Trial Results for Celiac-Disease Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2674642872","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674642872?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:35","pubTimestamp":1791804900,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics reported what it called positive top-line results from an early-stage trial of its treatment for celiac disease.The company said Monday its treatment, ANB033, achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms, compared with placebo.Shares of First Tracks jumped 17%, to $37.36, in premarket trading.First Tracks Chief Executive Daniel Faga said trace exposure to gluten can cause intestinal damage and debilitating systems for people living with celiac disease.\"After treatment with ANB033, patients underwent a 14-day gluten challenge consuming the equivalent of two slices of bread a day,\" Faga said. \"ANB033 achieved a statistically significant and clinically meaningful protective effect against gluten-induced intestinal damage and symptoms, while maintaining a favorable safety profile.\"First Tracks said its treatment prevented an increase in symptoms throughout the entire glute","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674874395","title":"First Tracks Says Anb033 Meets Key Histologic, Symptom Endpoints in Phase 1b Celiac Gluten-Challenge Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2674874395","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674874395?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:01","pubTimestamp":1791802877,"startTime":"0","endTime":"0","summary":"First Tracks says ANB033 meets key histologic, symptom endpoints in Phase 1b celiac gluten-challenge studyFirst Tracks Biotherapeutics reported positive top-line Phase 1b Cohort 1 results for ANB033 i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nNDL2dVBqd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BQXX3D17.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","SG9999014039.USD","IE00BKPKM429.USD","BK4112","IE00BN0W2V16.EUR","LU0314104364.USD","LU2095319765.USD","BK4585","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","NDAQ","SG9999014021.USD","BCDF","IE00BQXX3F31.USD","IE00BN0W2T93.GBP","TRAX","LU2210150020.SGD","BK4588","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674892874","title":"First Tracks Biotherapeutics - Anb033 Achieves Statistically Significant Protective Effect in Celiac Disease Phase 1B Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2674892874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674892874?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTWBCZ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674874890","title":"First Tracks Biotherapeutics - Anb033 Phase 2 Development in Vitiligo and Additional Indication to Initiate in H1 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2674874890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674874890?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTWBCZ:7","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674874845","title":"First Tracks Biotherapeutics - Anb033 Phase 1B Cohort in Eosinophilic Esophagitis Top-Line Data Expected Q3 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2674874845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674874845?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTWBCZ:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674874815","title":"First Tracks Biotherapeutics Announces Positive Top-Line Results for Anb033 in Gluten-Challenge Study in Celiac Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2674874815","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674874815?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTWBCZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674818874","title":"First Tracks Biotherapeutics - Anb033 Shows +0.49 Placebo-Adj Delta in Vh:Cd Ratio (p=0.009) at Week 6","url":"https://stock-news.laohu8.com/highlight/detail?id=2674818874","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674818874?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTWBCZ:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674748918","title":"First Tracks Biotherapeutics - Anb033 Well Tolerated with no Safety Signals Observed to Date","url":"https://stock-news.laohu8.com/highlight/detail?id=2674748918","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674748918?lang=en_us&edition=fundamental","pubTime":"2026-10-12 19:00","pubTimestamp":1791802801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261012:nTUABTWBCZ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674991879","title":"First Tracks Shares Climb Ahead of Early-Stage Trial Readout","url":"https://stock-news.laohu8.com/highlight/detail?id=2674991879","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674991879?lang=en_us&edition=fundamental","pubTime":"2026-10-12 18:13","pubTimestamp":1791799980,"startTime":"0","endTime":"0","summary":"Shares of First Tracks Biotherapeutics were higher after the company said it would review top-line data from a trial of its treatment for celiac disease on Monday.The stock rose 15%, to $36.71, in premarket trading. Through Friday's close, shares are up nearly 68% year to date.The company said late Friday that it will host an investor call and live webcast to review top-line data from the first cohort of an early-stage trial investigating its drug, ANB033, as a treatment for celiac disease.The call and webcast are scheduled for 8:30 a.m. Eastern on Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674287573","title":"Analysts Offer Insights on NA Companies: American Integrity Insurance Group, Inc. (AII) and First Tracks Biotherapeutics Inc (TRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674287573","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674287573?lang=en_us&edition=fundamental","pubTime":"2026-10-12 17:30","pubTimestamp":1791797419,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the NA sector as 2 analysts just weighed in on American Integrity Insurance Group, Inc. (AII) and First Tra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-american-integrity-insurance-group-inc-aii-and-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-na-companies-american-integrity-insurance-group-inc-aii-and-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4107","NA","TRAX","AII","BK4141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674846435","title":"First Tracks Biotherapeutics to Release Phase 1b Cohort 1 Data for Anb033 in Celiac Disease Oct. 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2674846435","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674846435?lang=en_us&edition=fundamental","pubTime":"2026-10-12 04:00","pubTimestamp":1791748824,"startTime":"0","endTime":"0","summary":"First Tracks Biotherapeutics to release Phase 1b cohort 1 data for ANB033 in celiac disease Oct. 12First Tracks Biotherapeutics will release top-line Cohort 1 data from its Phase 1b ANB033 celiac dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261011:nNDLXC3jQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","IE00B64PRP62.GBP","BK4112","IE00BQXX3D17.EUR","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","SG9999014005.SGD","IE00BQXX3F31.USD","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00BGHQF748.EUR","LU2210150020.SGD","IE00BN0W2T93.GBP","TRAX","SG9999014013.SGD","NDAQ","BK4585","LU2095319765.USD","BK4588","BK4139","IE00BN0W2W23.USD","LU0314104364.USD","IE00BN0W2V16.EUR","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674846438","title":"First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1B Trial of Anb033, a Cd122 Antagonist, in Celiac Disease on Oct. 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2674846438","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674846438?lang=en_us&edition=fundamental","pubTime":"2026-10-12 04:00","pubTimestamp":1791748801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261011:nTUABMMFZS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674858206","title":"Wells Fargo Keeps Their Buy Rating on First Tracks Biotherapeutics Inc (TRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674858206","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674858206?lang=en_us&edition=fundamental","pubTime":"2026-10-09 17:55","pubTimestamp":1791539725,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Derek Archila from Wells Fargo maintained a Buy rating on First Tracks Biotherapeutics Inc, with a price target of ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wells-fargo-keeps-their-buy-rating-on-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PGF","TRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674304908","title":"Analysts Conflicted on These NA Names: Amrize Ltd (AMRZ) and First Tracks Biotherapeutics Inc (TRAX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2674304908","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674304908?lang=en_us&edition=fundamental","pubTime":"2026-10-09 17:30","pubTimestamp":1791538215,"startTime":"0","endTime":"0","summary":"Companies in the NA sector have received a lot of coverage today as analysts weigh in on Amrize Ltd (AMRZ) and First Tracks Biotherapeutics Inc (TR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-amrize-ltd-amrz-and-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-conflicted-on-these-na-names-amrize-ltd-amrz-and-first-tracks-biotherapeutics-inc-trax-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PKB","AMRZ","TRAX","BK4141","BK4011","BK4139","NA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671047702","title":"First Tracks Biotherapeutics Inc : Canaccord Genuity Initiates Coverage with Buy Rating; Target Price $50","url":"https://stock-news.laohu8.com/highlight/detail?id=2671047702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671047702?lang=en_us&edition=fundamental","pubTime":"2026-09-30 20:43","pubTimestamp":1790772233,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nFWN45M0XQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TRAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":83,"code":"91000000","status":"200"}]}}